NCT06805825View on ClinicalTrials.gov

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

PHASE1RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

December 31, 2027

Conditions
Gastrointestinal Stromal TumorsSmall-cell Lung CancerAdenoid Cystic CarcinomaUveal MelanomaNeuroendocrine TumorsChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Interventions
DRUG

NN3201

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Trial Locations (5)

22031

ACTIVE_NOT_RECRUITING

NEXT Virginia, Fairfax

44106

RECRUITING

Case Comprehensive Cancer Center, Cleveland

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

97239

RECRUITING

Oregon Health & Science University, Portland

48109-9001

RECRUITING

University of Michigan Hospitals, Ann Arbor

Sponsors
All Listed Sponsors
lead

Novelty Nobility, Inc.

INDUSTRY

NCT06805825 - A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | Biotech Hunter | Biotech Hunter